KP Biomedical Engineering - Issue #17
-Gibson Area Hospital and Health Services Kicks off “Project One” with MEDITECH Expanse CANTON, Mass.--(BUSINESS WIRE)
--Gibson Area Hospital and Health Services (GAHHS) (Gibson City, IL), the nation’s 5th largest Critical Access Hospital, has signed for MEDITECH Expanse as its go-forward platform. GAHHS has a long and proud history of being an independent healthcare provider, recently celebrating its 72nd year servicing its communities.
-QT Imaging Holdings Announces New Commercial Shipment in Partnership with Couri Center NOVATO, Calif.--(BUSINESS WIRE)
--QT Imaging Holdings, Inc. (NASDAQ:QTI) a medical device company engaged in research, development, and commercialization of innovative body imaging systems is pleased to announce expansion of locations offering the Breast Acoustic CTTM Scanner to Couri Center for Gynecology and Integrative Women's Health, in Peoria, IL. The shipment was made together with our strategic business and distribution partner, NXC Imaging, Inc.
-AA Medical Appoints Jay Burkhardt as Chief Executive Officer CHICAGO--(BUSINESS WIRE)
--AA Medical, the leading tech-enabled solutions provider of medical equipment and supplies, is proud to announce the appointment of Jay Burkhardt as Chief Executive Officer. Burkhardt joins AA Medical from Probo Medical, a private equity backed global diagnostic imaging solutions provider, where he most recently held the role of President and Chief Operating Officer. He joined Probo Medical in 2019 and led the business through multiple phases of transformational growth.
-ACRO Releases Publication Showcasing Benefits of Centralized Monitoring Implementation Through Real-World Use Case WASHINGTON--(BUSINESS WIRE)
--ACRO’s RBQM Working Group has announced the publication of its latest RBM/RBQM paper, Risk-Based Quality Management: A Case for Centralized Monitoring, in DIA’s Therapeutic Innovation & Regulatory Science journal. In this new publication, ACRO’s RBQM Working Group provides a real-life example of centralized monitoring implementation using a clinical trial from clinicaltrials.gov.
-PanGIA Biotech Announces Landmark Partnership Agreement for First Liquid Biopsy Prostate Cancer Assay in India DELRAY BEACH, Fla.--(BUSINESS WIRE)
--PanGIA Biotech–a pioneer in liquid biopsy technology announced its first international partnership, collaborating with Canary Oncoceutics (Canary Oncoceutics, Inc., Phoenix, AZ, and Canary Oncoceutics India Pvt Ltd, Tamil Nadu, India). This collaboration introduces the PanGIA® Prostate Assay, the world’s first AI-integrated urine-based liquid biopsy for prostate cancer detection, marking its commercial debut in India.
-Tracer Biotechnologies Announces Agreement for Next-Generation Cancer Monitoring for Drug Development NEW YORK--(BUSINESS WIRE)
--Tracer Biotechnologies, a next-generation diagnostics company, announced a multi-year project with AstraZeneca (LSE/STO/Nasdaq: AZN). The agreement will enable AstraZeneca to use Tracer’s circulating tumor DNA (ctDNA) monitoring technology for clinical trials. Tracer has developed a proprietary platform for tumor-informed ctDNA detection based on digital polymerase chain reaction (PCR).
-Anteris Technologies Global Corp. Announces Pricing of U.S. Initial Public Offering BRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)
--Anteris Technologies Global Corp. (“ATGC”) announced the pricing of its initial public offering of 14,800,000 shares of its common stock (“Common Stock”) in the U.S. (the “Offering”), at an initial public offering price of $6.00 per share. The shares are expected to begin trading on the Nasdaq Global Market on December 13, 2024 under the ticker symbol "AVR."
-FDA Inspection and Audit Readiness Training for Medical Device Manufacturers Training Course (ONLINE EVENT: January 29, 2025/ON-DEMAND) - ResearchAndMarkets.com DUBLIN--(BUSINESS WIRE)
--The "Inspection and Audit Readiness Training for Medical Device Manufacturers-Live, Online Training" training has been added to ResearchAndMarkets.com's offering. This course focuses on identifying FDA inspection criteria, resources (including key standard operating procedures such as CP 7382.845) and practices used to plan, conduct, and assess inspections of medical device manufacturers. It walks participants through a "typical" new, tougher CGMP compliance audit.
-Aptamer Group announces new scientific advisory board members
--Aptamer Group plc, the developer of novel Optimer binders to enable innovation in the life sciences industry, has announced three new members to its Scientific Advisory Board (SAB).
-Neuroelectrics and Neuronostics partner to deliver integrated EEG solutions for clinical trials
--Neuroelectrics, a pioneer in high-definition brain stimulation and EEG technology, has partnered with Neuronostics, an innovator in advanced digital biomarkers and EEG analysis.
-Nanopore sequencing reveals cancer's molecular fingerprint for faster diagnosis
--Different types of cancer have unique molecular 'fingerprints' which are detectable in early stages of the disease and can be picked up with near-perfect accuracy by small, portable scanners in just a few hours, according to a study published today in the journal Molecular Cell.
-Metabolic imaging detects ovarian cancer subtypes and predicts chemotherapy response
--Study demonstrates how metabolic imaging differentiates high and low oxidative phosphorylation (OXPHOS) subtypes of high-grade serous ovarian cancer (HGSOC). By assessing metabolic activity, it also identifies early and variable responses to chemotherapy, improving precision in treatment strategies.
-New tool helps surgeons plan heart valve replacements with precision
--Scientists at Queen Mary University of London and Barts Health have developed an innovative tool that simulates blood flow in the aorta, helping heart surgeons plan surgeries more precisely.
-FunMap reveals new insights into cancer-associated genes and proteins
--Large-scale protein and gene profiling have massively expanded the landscape of cancer-associated proteins and gene mutations, but it has been difficult to discern whether they play an active role in the disease or are innocent bystanders.
-Caltech develops microrobots for precise drug delivery
--In the future, delivering therapeutic drugs exactly where they are needed within the body could be the task of miniature robots. Not little metal humanoid or even bio-mimicking robots; think instead of tiny bubble-like spheres.
-Penn-led consortium to advance imaging of brain diseases
--A Penn Medicine-led consortium of radiology and chemistry researchers across the United States will advance imaging of diseases like Parkinson's by testing radiotracers they identified that illuminate α-synuclein (αSyn) or 4R tau proteins on positron emission tomography (PET) scans.
-New technique enables laser light to penetrate deeper into living tissues
--Metabolic imaging is a noninvasive method that enables clinicians and scientists to study living cells using laser light, which can help them assess disease progression and treatment responses.
-electronRx to launch purpleDx pulmonary disease smartphone app for remote lung function monitoring
--electronRx, a leading digital medicine and biomarker company driving healthcare through pulmonary innovation, today announced that it will launch purpleDx, a cardiopulmonary assessment app built to medical device standards, at CES 2025 from 7-10 Jan in Las Vegas, USA.
-Implantable sensors aid in optimizing bone injury recovery
--Tiny implantable sensors are helping University of Oregon researchers optimize the process of recovery from severe bone injuries.
-Gene therapy to prevent stillbirth and premature delivery developed
--Researchers investigate the effectiveness of placental nano-based insulin-like 1 growth factor gene therapy to correct fetal growth restriction.
-Portable MRI and AI improve Alzheimer’s diagnosis with cost-effective precision
--Researchers optimized portable low-field MRI with machine learning to improve brain morphometry and white matter hyperintensity detection, making Alzheimer's diagnosis more accessible and cost-effective.
-Deep learning transforms PDAC diagnosis and treatment
--Researchers have successfully developed a deep learning model that classifies pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, into molecular subtypes using histopathology images.
-Harnessing the power of AI to optimize breast cancer management
--The future of breast cancer screening and risk-reducing strategies is being shaped by artificial intelligence (AI), according to a review article published by Cell Press on December 12 in the journal Trends in Cancer.
-DTI detects precancerous lesions in the pancreas
--Precursor lesions of pancreatic cancer are very difficult to characterize with magnetic resonance imaging (MRI). But now, in a new study, researchers led by Noam Shemesh and Carlos Bilreiro – respectively head of the Preclinical MRI lab at Champalimaud Research and a doctor at the Champalimaud Clinical Centre's Radiology Department – have shown, for the first time, that a particular form of MRI, called Diffusion Tensor Imaging (DTI), is capable of robustly detecting pre-malignant lesions in the pancreas.
-Pandemic fears see launch of innovative UK project to find new ways to test
--Chris Whitehouse, a political consultant and expert on medical technology policy and regulation at Whitehouse Communications, highlights an innovative new UK initiative to boost testing in the face of any new pandemic.
-Consultation launched on effectiveness of EU regulations on medical devices
--Chris Whitehouse, a political consultant and expert on medical technology policy and regulation at Whitehouse Communications showcases a new pan-EU consultation on the effectiveness of EU regulations on medical devices.
-Machine learning model predicts CDK4/6 inhibitor effectiveness in metastatic breast cancer
--A machine learning (ML) model incorporating both clinical and genomic factors outperformed models based solely on either clinical or genomic data in predicting which patients with hormone receptor (HR)-positive, HER2-negative metastatic breast cancer would have better outcomes from adding CDK4/6 inhibitors to endocrine therapy as first-line treatment, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.
-AI tool could revolutionize placenta examination and improve neonatal care
--A newly developed tool that harnesses computer vision and artificial intelligence (AI) may help clinicians rapidly evaluate placentas at birth, potentially improving neonatal and maternal care, according to new research from scientists at Northwestern Medicine and Penn State.